| Sarah Mcdermott, | |
|
733 N Main St Ste C, Bellevue, ID 83313-6068 | |
| (208) 788-0146 | |
| Not Available |
| Full Name | Sarah Mcdermott |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 733 N Main St Ste C, Bellevue, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023650538 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Mcdermott, 733 N Main St Ste C, Bellevue, ID 83313-6068 Ph: (208) 788-0146 | Sarah Mcdermott, 733 N Main St Ste C, Bellevue, ID 83313-6068 Ph: (208) 788-0146 |
News Archive
Fear response to traumatic or threatening situations helps us evade or escape danger. At the same time fear response is learned in the form of association between stimulus or situation and the presence of a stressor.
Eisai Co., Ltd. and Biogen Idec announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401.
Physicians and scientists have long searched the natural world for chemicals that can improve human health. However, evolutionary selection optimized natural chemicals to benefit their host, not for safety or efficacy in humans.
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
International research involving the University of Adelaide has uncovered a developmental abnormality in babies - especially in premature babies and in boys - that for the first time has been directly linked to cases of sudden infant death syndrome (SIDS).
› Verified 5 days ago
Kelle Schmidt, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 704 E Pine St, Bellevue, ID 83313 Phone: 575-650-0876 | |
Rachel Foster, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 733 N Main St Ste C, Bellevue, ID 83313 Phone: 208-737-9999 Fax: 208-736-4400 |